No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
GILD Obtains Positive CHMP Opinion for Liver Disease Drug
Gilead (GILD) Upgraded to Buy: Here's Why
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
The former global development head of Sanofi (SNY.US) has joined Gilead (GILD.US).
Before joining Gilead (GILD.US), Dr. Dietmar Berger served as CMO and Global Development Head at Sanofi (SNY.US).
Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report